Standard Artesunate Dosage Alone
Artesunate, an artemisinin derivative for severe malaria, is typically dosed intravenously at 2.4 mg/kg at 0, 12, and 24 hours, then daily until oral therapy starts.[1] Rectal or intramuscular routes use similar initial doses, adjusted for weight.
Dosage Adjustments with Common Antimalarials
Artesunate is rarely used alone and follows WHO guidelines pairing it with a partner drug to counter resistance. No major dose reductions occur, but regimens change based on the combination:
- With mefloquine: Artesunate 4 mg/kg/day for 3 days + mefloquine 25 mg/kg total (15 mg/kg day 2, 10 mg/kg day 3). Artesunate dose increases slightly from monotherapy for fixed-duration therapy.[2]
- With amodiaquine: Artesunate 4 mg/kg/day days 0-2 + amodiaquine 30 mg/kg total over 3 days. Standard without reduction.[2]
- With sulfadoxine-pyrimethamine (SP): Artesunate 4 mg/kg/day days 0-1 + single SP dose (25 mg/kg sulfadoxine/1.25 mg/kg pyrimethamine). Shortened artesunate course.[2]
These fixed combinations (e.g., artemether-lumefantrine as oral follow-up) maintain artesunate at 4 mg/kg/day initially, per WHO, without interactive dose changes.[1][2]
Adjustments for Renal or Hepatic Impairment in Combinations
- Mild-moderate renal/hepatic issues: No change needed; monitor closely.[3]
- Severe impairment: Reduce frequency to every 48 hours or switch to oral ACTs, as artesunate's rapid clearance (half-life ~0.5 hours) relies on liver metabolism. Evidence limited; case-by-case.[3][4]
Interactions Requiring Dosage Changes
Artesunate has few pharmacokinetic interactions, but some alter exposure:
| Interacting Drug/Class | Effect on Artesunate | Dosage Recommendation |
|------------------------|----------------------|-----------------------|
| Strong CYP2B6 inhibitors (e.g., nevirapine, ritonavir) | Increased artesunate levels (up to 2-fold AUC) | Monitor for toxicity; no routine reduction, but reduce if severe side effects.[5] |
| CYP2B6 inducers (e.g., rifampin) | Decreased levels | Increase artesunate dose by 50% or use alternative; limited data.[5] |
| Ketoconazole (CYP inhibitor) | 2.5-fold AUC increase | Consider 25-50% reduction in prolonged use; not standard in malaria.[5] |
| Mefloquine (partner drug) | No change; mefloquine unchanged by artesunate | Standard combo dosing.[6] |
No adjustments for food, antacids, or most antiretrovirals except strong CYP2B6 modulators.[3][5]
Special Populations in Combinations
- Children: Weight-based (e.g., <20kg: lower mefloquine split); no artesunate change.[2]
- Pregnancy: Full dose safe (category C); preferred for severe malaria.[1]
- Obesity: Use actual body weight up to 50-60kg max; adjust partners like mefloquine.[3]
Why Dosage Changes Are Rare
Artesunate's short half-life and rapid parasite clearance minimize accumulation risks. Adjustments focus on partners or extremes like organ failure, driven by PK studies showing low interaction potential.[4][5]
Sources
[1]: WHO Malaria Treatment Guidelines (2022)
[2]: WHO Artesunate Combinations
[3]: Drugs.com Artesunate Dosing
[4]: FDA ArtesunatePyronaridine Label
[5]: Clinical Pharmacology Review - Artesunate
[6]: PubMed: Artesunate-Mefloquine PK